dpp-4 inhibitors vs. glp-1 agonist receptor versus inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes How do SGLT-2 inhibitors, GLP-1
Description
Griffith, D
These results are the basis for a positioning of the DPP-4 inhibitors as second-line therapy for the treatment of type 2 diabetes, especially, when hypoglycaemia should strictly be avoided (see section below)

Politics1 year ago Which Types of Government Rule the World
Xue S, Wasserfall CH, Parker M, Brusko TM, McGrail S, McGrail K, et al

Compounded semaglutide: Contains the same active ingredient as both Ozempic and Wegovy, bypassing some of the brand-name coverage issues

Subramaniam SR, Chesselet MF
